4/6
05:38 pm
alms
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results [Yahoo! Finance]
Medium
Report
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results [Yahoo! Finance]
3/30
10:20 am
alms
Alumis (ALMS) had its price target raised by Oppenheimer Holdings, Inc. from $50.00 to $55.00. They now have an "outperform" rating on the stock.
High
Report
Alumis (ALMS) had its price target raised by Oppenheimer Holdings, Inc. from $50.00 to $55.00. They now have an "outperform" rating on the stock.
3/30
08:13 am
alms
Alumis (ALMS) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.
High
Report
Alumis (ALMS) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.
3/30
08:02 am
alms
Alumis (ALMS) had its price target lowered by HC Wainwright from $40.00 to $25.00. They now have a "buy" rating on the stock.
High
Report
Alumis (ALMS) had its price target lowered by HC Wainwright from $40.00 to $25.00. They now have a "buy" rating on the stock.
3/29
09:19 pm
alms
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout [Yahoo! Finance]
High
Report
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout [Yahoo! Finance]
3/28
01:38 pm
alms
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis [Yahoo! Finance]
High
Report
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis [Yahoo! Finance]
3/28
01:30 pm
alms
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
High
Report
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
3/20
09:24 am
alms
Alumis (ALMS) had its price target raised by Morgan Stanley from $33.00 to $38.00. They now have an "overweight" rating on the stock.
Medium
Report
Alumis (ALMS) had its price target raised by Morgan Stanley from $33.00 to $38.00. They now have an "overweight" rating on the stock.
3/20
08:26 am
alms
Alumis (ALMS) had its price target raised by Chardan Capital from $37.00 to $38.00. They now have a "buy" rating on the stock.
Low
Report
Alumis (ALMS) had its price target raised by Chardan Capital from $37.00 to $38.00. They now have a "buy" rating on the stock.
3/19
04:55 pm
alms
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements [Yahoo! Finance]
Low
Report
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements [Yahoo! Finance]
3/19
04:05 pm
alms
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Low
Report
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
3/18
08:45 am
alms
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting [Yahoo! Finance]
Low
Report
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting [Yahoo! Finance]
3/18
08:00 am
alms
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
Low
Report
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
3/10
05:04 pm
alms
Alumis (ALMS) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Medium
Report
Alumis (ALMS) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
3/2
08:05 am
alms
Alumis to Present at the Leerink Partners Global Healthcare Conference
Low
Report
Alumis to Present at the Leerink Partners Global Healthcare Conference
2/26
08:29 pm
alms
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference [Yahoo! Finance]
Low
Report
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference [Yahoo! Finance]
2/25
08:00 am
alms
Alumis (ALMS) is now covered by Stifel Nicolaus. They set a "buy" rating and a $44.00 price target on the stock.
Medium
Report
Alumis (ALMS) is now covered by Stifel Nicolaus. They set a "buy" rating and a $44.00 price target on the stock.
2/5
08:05 am
alms
Alumis to Participate in Upcoming February Investor Conferences
Low
Report
Alumis to Participate in Upcoming February Investor Conferences
1/22
07:48 am
alms
Alumis (NASDAQ:ALMS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Alumis (NASDAQ:ALMS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
1/21
08:42 am
alms
Alumis (NASDAQ:ALMS) was given a new $37.00 price target on by analysts at Loop Capital.
Low
Report
Alumis (NASDAQ:ALMS) was given a new $37.00 price target on by analysts at Loop Capital.
1/21
07:17 am
alms
Alumis (NASDAQ:ALMS) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock.
Low
Report
Alumis (NASDAQ:ALMS) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock.
1/21
06:06 am
alms
Alumis (NASDAQ:ALMS) was given a new $37.00 price target on by analysts at Chardan Capital.
Low
Report
Alumis (NASDAQ:ALMS) was given a new $37.00 price target on by analysts at Chardan Capital.